Form 4: Oruka Therapeutics Executive Sells Shares
Insider Transaction (Form 4)
Joana Goncalves, Chief Medical Officer of Oruka Therapeutics, Inc., sold 7,000 shares of common stock on October 15, 2026.
Summary
- Option exercise/conversion: acquired 3,500 Common Stock at $6.84 ($23,940) on October 15, 2026; holds 35,271 after (Direct).
- Option exercise/conversion: acquired 3,500 Common Stock at $7.80 ($27,300) on October 15, 2026; holds 38,771 after (Direct).
- Open-market sale: disposed of 2,853 Common Stock at $73.89 ($210,806) on October 15, 2026; holds 35,918 after (Direct).
- Open-market sale: disposed of 1,847 Common Stock at $74.69 ($137,957) on October 15, 2026; holds 34,071 after (Direct).
- Open-market sale: disposed of 1,400 Common Stock at $75.48 ($105,677) on October 15, 2026; holds 32,671 after (Direct).
- Open-market sale: disposed of 700 Common Stock at $76.67 ($53,666) on October 15, 2026; holds 31,971 after (Direct).
- Open-market sale: disposed of 200 Common Stock at $77.71 ($15,542) on October 15, 2026; holds 31,771 after (Direct).
- Option exercise/conversion: disposed of 3,500 Employee Stock Option (right to buy) on October 15, 2026; holds 190,063 after (Direct).
- Option exercise/conversion: disposed of 3,500 Employee Warrant (right to buy) on October 15, 2026; holds 161,492 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $523,648 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Joana Goncalves — Officer (Chief Medical Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-15 | Option exercise/conversion | Common Stock | 3,500 | $7 | $23.9K | 35,271 |
| 2026-10-15 | Option exercise/conversion | Common Stock | 3,500 | $8 | $27.3K | 38,771 |
| 2026-10-15 | Open-market sale | Common Stock | 2,853 | $74 | $210.8K | 35,918 |
| 2026-10-15 | Open-market sale | Common Stock | 1,847 | $75 | $138.0K | 34,071 |
| 2026-10-15 | Open-market sale | Common Stock | 1,400 | $75 | $105.7K | 32,671 |
| 2026-10-15 | Open-market sale | Common Stock | 700 | $77 | $53.7K | 31,971 |
| 2026-10-15 | Open-market sale | Common Stock | 200 | $78 | $15.5K | 31,771 |
| 2026-10-15 | Option exercise/conversion | Employee Stock Option (right to buy) | 3,500 | — | — | 190,063 |
| 2026-10-15 | Option exercise/conversion | Employee Warrant (right to buy) | 3,500 | — | — | 161,492 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-15 | Option exercise/conversion (3,500 shares) |
| 2026-10-15 | Option exercise/conversion (3,500 shares) |
| 2026-10-15 | Open-market sale (2,853 shares) |
| 2026-10-15 | Open-market sale (1,847 shares) |
| 2026-10-15 | Open-market sale (1,400 shares) |
| 2026-10-15 | Open-market sale (700 shares) |
| 2026-10-15 | Open-market sale (200 shares) |
| 2026-10-15 | Option exercise/conversion (3,500 shares) |
| 2026-10-15 | Option exercise/conversion (3,500 shares) |
Keywords
insider transaction, Form 4, ORKA, Oruka Therapeutics, Inc., bearish, Joana Goncalves
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.